A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk.
ELISA
ELLA
adiponectin
breast cancer risk
immunoassay platform
leptin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jun 2021
30 Jun 2021
Historique:
received:
10
05
2021
revised:
11
06
2021
accepted:
29
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Adiponectin and leptin are adipokines secreted by the adipose tissue that are associated with several chronic diseases including cancer. We aimed to compare the immunoassay platform ELLA with an enzyme-linked immunosorbent assay (ELISA) kit and to assess whether the results of the association analyses with breast cancer risk were dependent on the assay used. We measured adiponectin and leptin with ELLA and ELISA on baseline serum samples of 116 Italian postmenopausal women enrolled in two international breast cancer prevention trials. Results were compared with Deming, Passing-Bablok regression and Bland-Altman plots. Disease-free survival was analyzed with the Cox model. There was a good correlation between the methods for adiponectin and leptin (r > 0.96). We found an increased breast cancer risk for very low adiponectin levels (HR for ELLA = 3.75; 95% CI: 1.37;10.25,
Identifiants
pubmed: 34209441
pii: cancers13133303
doi: 10.3390/cancers13133303
pmc: PMC8268385
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : GR-2013-02358807
Références
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Medicine (Baltimore). 2019 Feb;98(6):e14359
pubmed: 30732167
J Pharm Biomed Anal. 2011 Jul 15;55(5):869-77
pubmed: 21530130
Lancet Public Health. 2018 Oct;3(10):e490-e497
pubmed: 30177479
Lancet. 2016 Feb 27;387(10021):866-73
pubmed: 26686313
Clin Chem. 1998 May;44(5):1024-31
pubmed: 9590376
Clin Chim Acta. 2017 Feb;465:30-33
pubmed: 27986548
Clin Chem. 2005 Jul;51(7):1102-9
pubmed: 15976097
Diabetes Care. 2007 Feb;30(2):280-5
pubmed: 17259495
Scand J Clin Lab Invest. 2011 May;71(3):221-6
pubmed: 21288160
Lancet. 2014 Mar 22;383(9922):1041-8
pubmed: 24333009
Clin Proteomics. 2015 Dec 11;12:28
pubmed: 26692826
J Clin Oncol. 2012 Jan 10;30(2):151-7
pubmed: 22162577
Metabolism. 2019 Mar;92:61-70
pubmed: 30586573
Peptides. 2015 Oct;72:4-15
pubmed: 25908411
Int J Epidemiol. 2014 Aug;43(4):1226-36
pubmed: 24737805
Ann Oncol. 2018 Feb 1;29(2):504-509
pubmed: 29126161
BMC Public Health. 2009 Mar 25;9:88
pubmed: 19320986
Medicine (Baltimore). 2018 Jul;97(29):e11433
pubmed: 30024516
Biochem Med (Zagreb). 2011;21(1):49-52
pubmed: 22141206
Clin Chem. 1993 Mar;39(3):424-32
pubmed: 8448852
Clin Exp Pharmacol Physiol. 1997 Feb;24(2):193-203
pubmed: 9075596
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Medicine (Baltimore). 2019 Feb;98(5):e14094
pubmed: 30702563
Obes Res Clin Pract. 2019 Jul - Aug;13(4):329-339
pubmed: 31003933
Am J Reprod Immunol. 2016 Jun;75(6):678-93
pubmed: 27170460
Clin Chem. 2004 Jan;50(1):219-21
pubmed: 14709655
Diabetes Metab. 2017 Sep;43(4):395-397
pubmed: 28089503
Nature. 1994 Dec 1;372(6505):425-32
pubmed: 7984236
Medicine (Baltimore). 2018 Jul;97(27):e11345
pubmed: 29979411
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1321-1328
pubmed: 32277008
PLoS One. 2013 Jun 27;8(6):e67349
pubmed: 23826274
Oncotarget. 2017 May 13;8(43):75389-75399
pubmed: 29088874
J Clin Lab Anal. 2016 May;30(3):254-7
pubmed: 25821014
Biochem Med (Zagreb). 2015 Jun 05;25(2):141-51
pubmed: 26110027
Clin Chim Acta. 2006 Nov;373(1-2):121-6
pubmed: 16797517
J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56
pubmed: 15181022
Cell Metab. 2016 May 10;23(5):770-84
pubmed: 27166942
J Clin Chem Clin Biochem. 1983 Nov;21(11):709-20
pubmed: 6655447
Clin Chem Lab Med. 2010 Oct;48(10):1439-46
pubmed: 20575747